CASE COMMENTS: MERGERS – EUROPEAN UNION – PHARMACEUTICAL SECTOR – MARKET DEFINITIONS

Phase I: The European Commission authorizes, following a phase I review and subject to remedies, two mergers in the pharmaceutical sector (GlaxoSmithKline / Pfizer Consumer Healthcare Business, AbbVie / Allergan)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. The Commission has recently decided on two transactions in the pharmaceutical sector, both of which have been cleared subject to divestitures: the acquisition of Allergan by Abbvie and the acquisition of Pfizer's consumer health division by GlaxoSmithKline (GSK). Although they concern very different markets and products, these two decisions each provide a useful reminder of the analytical framework applicable to mergers between pharmaceutical companies and illustrate the particularities of this sector. GSK / Pfizer Consumer Healthcare Business: analysis of current competition between products with strong brand image GSK's and the Target's activities

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Hogan Lovells (Paris)
  • Hogan Lovells (Paris)

Quotation

Eric Paroche, Céline Verney, Phase I: The European Commission authorizes, following a phase I review and subject to remedies, two mergers in the pharmaceutical sector (GlaxoSmithKline / Pfizer Consumer Healthcare Business, AbbVie / Allergan), 10 January 2020, Concurrences N° 3-2020, Art. N° 96305, pp. 126-127

Visites 67

All reviews